Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors
Sign Up to like & getrecommendations! Published in 2018 at "Pancreas"
DOI: 10.1097/mpa.0000000000001115
Abstract: Objectives An integrated protocol combining capecitibine-temozolomide with yttrium-90 radioembolization (CapTemY90) for liver-dominant grade 2 neuroendocrine tumors (NETs) was designed in the hope of achieving synergistic improvement in liver disease control with no more than additive… read more here.
Keywords: yttrium radioembolization; neuroendocrine tumors; liver dominant; liver ... See more keywords
Abstract CT190: Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct190
Abstract: The TG6002.03 trial is a dose-escalation phase 1 clinical trial of TG6002 infusion via the hepatic artery in patients with liver-dominant colorectal cancer metastases. TG6002 is an engineered Copenhagen strain oncolytic Vaccinia virus, deleted of… read more here.
Keywords: day; artery; liver dominant; colorectal cancer ... See more keywords
Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
Sign Up to like & getrecommendations! Published in 2018 at "Anticancer research"
DOI: 10.21873/anticanres.12563
Abstract: AIM To compare toxicity, response, and survival outcomes of patients with hepatic metastases from breast cancer who underwent transarterial chemoembolization (TACE) or radioembolization (TARE). MATERIALS AND METHODS A retrospective review was carried out of all… read more here.
Keywords: tace; breast; breast cancer; dominant breast ... See more keywords